Committees

  • Acute Leukemia: Cellular therapy for acute leukemias, preleukemia and myelodysplastic disorders.
    Proposed Chair: Egypt
  • Chronic Leukemia: Cellular therapy for chronic leukemias and myeloproliferative disorders.
    Proposed Chair: Egypt
  • Lymphoma: Cellular therapy for Hodgkin’s and non-Hodgkin’s lymphoma.
    Proposed Chair: Lebanon
  • Plasma Cell Disorders: Cellular therapy for multiple myeloma and other plasma cell disorders.
    Proposed Chair: Tunisia
  • Pediatric Cancer: Cellular therapy for childhood malignancies and other issues related to use of cellular therapy in children.
    Proposed Chair: Jordan
  • Immune Deficiencies/Inborn Errors: Cellular therapy for congenital and acquired immune deficiencies and inborn errors of metabolism.
    Proposed Chair: Oman
  • Infection/Immune Reconstitution: Prevention and treatment of post-transplant infections and issues related to recovery of immune function.
    Proposed Chair: Morocco
  • HSCT/Graft vs. Host Disease and Transplantation related toxicity: Preparative regimens, prevention and treatment of early non-GVHD toxicities, acute and chronic GVHD.
    Proposed Chair: Iran
  • Bone marrow failure disorders: Cellular therapy for congenital and acquired bone marrow failure disorders in adult and pediatric age group.
    Proposed Chair: Saudi Arabia
  • Late effects, Supportive care and Quality of Life: Issues related to long term survivors of cellular therapy, including clinical and psychological effects of transplantation and HSCT supportive care.
    Proposed Chair: Saudi Arabia
  • Hemoglobinopathies: Cellular therapy for B-Thalassemia, Sickle Cell Anemia and other hemoglobin disorders.
    Proposed Chair: Iran
  • Histocompatibility, Alternate Donor Transplantation, Donor health.
    Proposed Chair: Iran